IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
Healthcare › Biological Products, (No Diagnostic Substances)
Price History
Feb 9, 2026 — Aug 25, 2026Investment Snapshot
- P/B of 2.52 — trading above book value
- Piotroski F-Score 4/9 — moderate financial health
- Loss-making — negative ROE of -44.7%
- Revenue growing at 61% annually
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) is a Healthcare company operating in Biological Products, (No Diagnostic Substances), listed on the NASDAQ , with a market capitalisation of $1.9 billion . Key value metrics: P/B ratio 2.52, Piotroski F-Score 4 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
IOVANCE BIOTHERAPEUTICS, INC. — Fundamental Analysis Summary
On financial health, IOVA shows a moderate Piotroski F-Score of 4/9, and negative return on equity of -44.7% (sector average: -20.1%), and manageable leverage with a debt-to-equity ratio of 0.31.
StockPik's composite Value Score for IOVA is 47/100 — reflecting current market or financial concerns. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
IOVA reports a moderate gross margin of 39.2% (sector average: 37.4%) and a negative operating margin of -114.6%.
IOVA shows revenue growing at 61% year-over-year, with earnings declining at 5%.